Preferential Treatment for US-Made Drugs in Health Programs
This bill aims to establish a pilot program that prioritizes drugs manufactured in the United States within Medicare, Medicaid, and CHIP programs. This means citizens using these programs might have easier access to domestically produced medications, potentially impacting treatment availability and costs, while also supporting local pharmaceutical manufacturing.
Key points
US-manufactured drugs may receive preferential treatment in Medicare, Medicaid, and CHIP, potentially lowering patient costs.
The pilot program will run for at least 7 years in a minimum of 8 states to assess its effectiveness.
The act seeks to enhance drug supply security, especially for critical medications, by supporting domestic production.
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens
(explained here).
Start recording it now.